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Abstract
Background: Surgical trials have typically experienced recruitment difficulties when compared with other types of
oncology trials. Qualitative studies have an important role to play in exploring reasons for low recruitment,
although to date few such studies have been carried out that are embedded in surgical trials.
The BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy) is a study to determine the
feasibility of randomisation to open versus laparoscopic access/robotic cystectomy in patients with bladder cancer.
We describe the results of a qualitative study embedded within the clinical trial that explored why patients decline
randomisation.
Methods: Ten semi-structured interviews with patients who declined randomisation to the clinical trial, and two
interviews with recruiting research nurses were conducted. Data were analysed for key themes.
Results: The majority of patients declined the trial because they had preferences for a particular treatment arm,
and in usual practice could choose which surgical method they would be given. In most cases the robotic option
was preferred. Patients described an intuitive ‘sense’ that favoured the new technology and had carried out their
own inquiries, including Internet research and talking with previous patients and friends and family with medical
backgrounds. Medical histories and lifestyle considerations also shaped these personalised choices. Of importance
too, however, were the messages patients perceived from their clinical encounters. Whilst some patients felt their
surgeon favoured the robotic option, others interpreted ‘indirect’ cues such as the ‘established’ reputation of the
surgeon and surgical method and comments made during clinical assessments. Many patients expressed a wish for
greater direction from their surgeon when making these decisions.
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Conclusion: For trials where the ‘new technology’ is available to patients, there will likely be difficulties with
recruitment. Greater attention could be paid to how messages about treatment options and the trial are conveyed
across the whole clinical setting. However, if it is too difficult to challenge such messages, then questions should be
asked about whether genuine and convincing equipoise can be presented and perceived in such trials. This calls
for consideration of whether alternative methods of generating evidence could be used when evaluating surgical
techniques which are established and routinely available.
Trial registration: Trial registration number: ISRCTN38528926 (11 December 2008).
Keywords: Qualitative, RCT, Bladder cancer, Surgery, Randomisation
Background
Surgical trials have typically experienced recruitment
difficulties compared with other types of oncology tri-
als in the UK [1]. There are several reasons for this
suggested in the medical literature. On the one hand,
the culture amongst surgeons is considered to be less
research oriented, and surgeons less experienced in
conducting trials, compared with other clinical spe-
cialties engaged in cancer medicine [1]. There are also
specific challenges with using randomised trials to
compare types of surgery, such as the impracticalities
of blinding, resistance to randomisation amongst sur-
gical teams, difficulties attaining clinical equipoise,
and the enhanced training that is necessary for new
treatments [1]. Following this, clinicians may also
need to accept that there is uncertainty or equipoise
about treatments that are established in usual practice
[2]. That said, there are examples of current recruit-
ment ‘success stories’ in surgical oncology trials [3],
and novel attempts to incorporate blinding into such
trials [4], suggesting that such challenges are not
necessarily insurmountable. Finding ways to improve
the evidence base for surgical procedure is imperative
[1, 3], as is the need to do so in ways which minimise
‘research waste’ [5–7]. Improving the efficiency of trial
processes, including recruitment, is one such way of
accomplishing this, although to date this remains a
‘largely evidence-free zone’ [8].
Qualitative research has an important role to play in in-
vestigating and addressing recruitment issues in trials.
Studies investigating patient perceptions and experiences
of surgical trials have helped illuminate why such trials
experience difficulties recruiting [2, 9–13]. In the ProtecT,
SPARE and QUEST trials (trials in prostate cancer, blad-
der cancer and breast reconstruction surgery) patient pref-
erences for particular treatment options undermined
recruitment into these trials [2, 10–13]. In the ProtecT
and SPARE trials recruiters were found to unwittingly pass
on their preferences to patients [10, 12], including the use
of ‘loaded’ terminology [2, 11]. In the CLasP trial (which
compared treatments for men with symptoms of benign
prostatic disease) it was also observed that clinicians
played a role in eliciting preferences and deciding who
could participate [9].
Participants in these trials also experienced difficulties
with the concept of randomisation. Whilst participants
understood the principles of randomised design (i.e,
chance, comparison and equipoise) [10], they struggled
to accept randomisation because they could not accept
‘equipoise’; that the clinician was genuinely uncertain
and the treatments similarly effective [2, 10, 11]. Partici-
pants in one trial also had expectations that their clinical
appointments would be used to make individualised
treatment decisions [9]. Such examples, therefore, sug-
gest that it is not necessarily patient (mis)understandings
of trial/medical information that is critical to patient
decision-making, as is often assumed [11], but the cul-
turally situated expectations that patients have of their
‘experts’; an argument which has been well-developed in
qualitative research investigating public uptake of sci-
ence [14–16]. This and other research also usefully high-
lights the different types of expertise, knowledge and
forms of reasoning that people draw upon and develop
when confronted with illness or perceived threats to
their health and wellbeing [17–20], including ‘experience
based expertise’ [17] and the culturally framed, personal,
subjective and social knowledge, often described as ‘lay
knowledge’ [18, 19].
The BOLERO trial (Bladder cancer: Open versus
Laparoscopic or RObotic cystectomy) is a feasibility
study that was developed on behalf of the National Can-
cer Research Institute (NCRI) Bladder Clinical Studies
Group and funded by Cancer Research UK, coordinated
by the Wales Cancer Trials Unit and Marie Curie Pallia-
tive Care Research Unit. The study aim was to deter-
mine the feasibility of randomisation to open versus
minimal access (laparoscopic or robotic) cystectomy in
patients with invasive bladder cancer, aged 18 or over.
The secondary aims were to assess the safety and effi-
cacy of minimal access cystectomy, and the reasons for
non-acceptance of randomisation [21]. Open and min-
imal access surgery were routinely available to all
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patients in our six participating trial sites, regardless of
whether or not they entered the study. Some of these
centres were also offering robotic surgery to their pa-
tients (trial and non-trial); at the other centres laparo-
scopic was the only minimal access option available.
The trial was designed with a quantitative primary end-
point of feasibility of randomisation, defined as >60 % of
patients accepting randomisation, which would be used to
determine whether a future randomised phase III trial,
requiring many hundreds of patients, was possible to
achieve. Within this trial an embedded qualitative study
was included to explore factors relating to a decision to
decline randomisation and patient experiences of trial
recruitment processes. Although not designed to identify
and implement changes to the feasibility trial, as in other
studies [2, 10–13], it was intended that the findings could
be used to make trial specific recommendations for im-
proving recruitment practices and documentation should
the trial have progressed to a full trial and more broadly
be used to inform the design and conduct of similar trials
in the future by contributing to the small amount of evi-
dence in this area. A more detailed description of trial
design is available on-line [21] and the quantitative out-
come, including activity and safety of the treatment arms,
will be reported elsewhere. For the background purposes
of this paper, however, it is reported that the threshold of
>60 % of patients accepting randomisation was not
reached, and a full phase III trial would not, therefore, be
considered feasible. This paper reports the qualitative out-
come which not only enhances understandings of recruit-
ment issues relating to this particular trial, but more
widely, adds to the qualitative evidence described above,
and identifies implications for the evaluation of similar
surgical/technology interventions in the future.
Methods
The aim of the qualitative study was to explore factors
relating to a decision not to consent to randomisation
between open surgery and minimal access surgery (robotic
or laparoscopic), and participants’ experiences of recruit-
ment processes in the BOLERO trial. The embedded
qualitative design involved semi-structured interviews
with up to 20 patients and an in-depth thematic approach
to analysis of the data. This research was informed by a
phenomenological perspective and interest in exploring
the lived experiences of participants and their decision-
making in the context of their life experiences, values and
beliefs. For the purposes of this paper and our clinical
audience, however, our results are presented as group
themes which cut across patients’ views and experiences,
but where relevant also identify the salient life context and
stories of individual participants in relation to the theme
being discussed.
Ethical approval for the BOLERO trial (including the
qualitative study) was granted by South East Wales
Research Ethics Committee in May 2010, and the trial was
sponsored by Cardiff University. Ten participants were
recruited into the qualitative study from three (out of a
potential six) sites which were recruiting into the main
BOLERO trial. Robotic surgery was not available at one of
these three sites. The interviews were conducted between
October 2011 and December 2012, and included eight
male and two female participants, with an age range of 44
to 74, and a mean age of 63.5 years. Participants (P)2 and
P10 were the only patients from the site without robotic
surgery; all other participants had the option of receiving
robotic surgery.
Informed consent was obtained for all participants. All
patients who declined randomisation into the main BO-
LERO trial were given information about the qualitative
study by their research nurse. Patients who wanted to
participate in the qualitative study were consented into
the study by their research nurse before being contacted
by the qualitative researcher to make interview arrange-
ments. When the minimum number of participants was
deemed sufficient for meaningful analysis, and theoret-
ical saturation was reached, recruitment was closed to
the qualitative study. Just under a quarter of the patients
who were eligible for this qualitative study participated
in an interview.
In response to initial slow recruitment to the qualitative
study, the study protocol was also amended to include a
further study involving semi-structured interviews with
the six research nurses recruiting to the BOLERO trial.
Research nurses have immediate experience of screening,
providing trial information to, and consenting prospective
participants. In this trial, the research nurses would talk
through the trial information in detail with patients, after
the surgeon or another member of the clinical team had
introduced and explained the trial to the patient during
their clinical consultation. They were typically also the
first point of contact for patients once they had made a
decision on whether or not to enter the trial. It was thus
considered that they would have good experience-based
knowledge of why patients declined or accepted random-
isation to the trial, as well as views on the process of pre-
senting and explaining the trial information, and any
difficulties that this may present. Semi-structured inter-
views with the research nurses involved in this trial were
used to explore their views and experiences with regards
to recruitment and to provide insights into any problems
and issues specific to this aspect of the trial.
Ten semi-structured interviews were carried out with pa-
tients in a location of the participants’ choice; patient’s
homes (n = 4); their place of work (n = 1) and by telephone
(n = 5). Interviews were conducted by a female researcher
with experience in cancer and healthcare research, but no
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clinical background. Interviews lasted between 20 and
45 minutes and explored patients’ experiences of trial infor-
mation and recruitment processes, reasons for declining
randomisation into the main trial and attitudes towards
medical research (interview topics summarised in Table 1).
Interviews were audio-recorded, transcribed verbatim
and uploaded to NVivo 9 software. Data analysis was
undertaken by two researchers who shared the analysis
of transcripts, following an in-depth thematic approach
[22]. Group results were analysed for consistent themes
using techniques of coding and comparison. A coding
framework for emergent themes was developed by the
researcher. This was an iterative process, moving be-
tween the data and the analytical concepts to develop
codes and concepts grounded in the data. Higher level
abstractions of codes were decided and results were veri-
fied by the research team by independent review of a
selection of transcripts.
Unfortunately, only two of the six research nurses
agreed to take part in an interview and one of these inter-
views failed to record; the data from this interview are
from notes taken during the interview and written up by
the researcher from memory immediately afterwards. This
seriously limits the contribution of these interviews to the
study results. However, although this data cannot be inter-
preted as ‘findings’ in their own right, they do provide
some useful context for the findings of the patient inter-
view study and are reported as such.
Results
Understandings of and attitudes towards trials
In general, these study participants were well-informed
and had a good understanding and appreciation of the
trial and medical research in general. Participants were
satisfied with the study information which they were
given and felt comfortable asking questions, although
some also described feeling overloaded by the amount of
clinical and trial information which they received at this
time and needed to consider in their decision-making:
I did fully understand um enough um to be going on
with. What I did feel that I was overloaded with
information from everything it was another lot of
information I had to take on board, if you see what I
mean because there were so many other things I had
to think about, about what sort of bladder I was going
to have, whether it was going to work you know, all
this sort of thing going on as well um so this was just
yet another thing I had to sort of um you know think
about. (P9)
Most participants recognised the value of research for
generating evidence to improve treatments for future
generations, and several patients had previously partici-
pated in other medical research studies. Most partici-
pants seemed to correctly understand the purpose of
the BOLERO trial as being to compare the different
types of surgery, and felt happy with their level of un-
derstanding. Participants understood the basic concept
of randomisation as having treatment allocation left to
chance. Some patients made sense of randomisation as
a ‘50-50 split’, while others stressed the role of the com-
puter, and made use of metaphors of ‘pot luck’ and ‘let-
ting the dice decide’ to make sense of the process:
When (research nurse) said it was a 50/50 split, you
know random split and I might actually, having had
all these tests and think how good this procedure was,
I might actually be put back into a 50 % of having the
more invasive surgery. (P6)
Choosing keyhole and robotic surgery
The main reason for patients declining the trial was
because they had developed a preference for the type of
surgical method they wanted and in usual practice could
Table 1 Summary of interview topics
Topics for patient interviews Topics for nurse interviews
Trial information and recruitment processes
• Experience of being told about the trial
• Understandings of trial purpose and principles,
e.g. randomisation
• Views on participant information sheet
• Other sources of information accessed about
types of surgery/trial
• Prior knowledge of and preferences for surgical methods
Decision-making
• Reasons for declining randomisation
• Choice of surgery and reasons given
• Influence of clinical team and others on decision-making
• Reflection on choices made and decision-making process
Experience of and attitudes towards medical research
• Views on randomisaton as process of allocating treatment
• Participation in previous and (potential) future research studies
Recruitment practices
• Professional background and time on trial
• Own and others’ duties and responsibilities with regard to the trial
• Description and reflection on information giving process for trial/other
options available to patients
Patient responses
• Recall of patient responses to trial information
• Views on patients’ reasons for declining randomisation
• Views on patients’ reasons for accepting randomisation
• Reflection on differences between patients who accept/decline trial
General reflections
• Compare and contrast with recruitment experiences of other trials
• Key challenges of this trial and suggestions for future trial design
and conduct
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choose which method they would receive. With the excep-
tion of one patient who opted for open surgery, all other
patients chose keyhole and where it was available opted for
robotic surgery. However, one of these patients ultimately
rejected surgery altogether, choosing to receive bacille
Calmette-Guérin (BCG) therapy instead (a vaccine given
directly into the bladder). These patients were thus unwill-
ing to relinquish control by accepting randomisation and
with it the possibility that they might not receive their pre-
ferred option:
If you didn’t know about it as you know if, if, if you
surgical team were randomising what they did and I
would never know then that would have been an
irrelevance to me but once I knew there was a choice.
I wanted to exercise that choice. (P3)
In line with the perspectives of patients recruited from
the same centre, one of the nurses described strong patient
preferences for robotic surgery, which they considered to
be the key factor undermining trial recruitment. This was
attributed to the fact that the centre was already offering
robotic surgery to patients, which made it difficult to con-
vey messages of equipoise and uncertainty when discussing
the trial:
I think because they’re offered the robot initially (.)
although they are told you know that normally here it
is robotic surgery um that sort of (.) sort of seals the
deal if you will … the patients think well the robot’s
here I might as well have that. (RN2)
Both nurses considered that many patients felt uncom-
fortable leaving surgery decisions to chance when the al-
ternative was to make an informed choice and could opt
for their preferred treatment with guidance from their
clinical team:
The main reason is that they know they can have the
robot here anyway and some don’t like the fact that
it’s being chosen for them you know that it’s basically
a computer saying right this is what will happen.
(RN2)
Patient preferences for type of surgery were linked to
their understandings of the different risks and benefits
attached to each method. Most patients saw the benefits
of keyhole/robotic to be that it was less invasive, more
precise, and requiring smaller cuts. This was understood
to mean that there would be less scarring, smaller risk of
infection and a shorter recovery period than for open
surgery. The only patient who preferred open surgery,
by contrast, considered that he would prefer to have one
big scar as opposed to multiple small scars:
I wanted the best option and the least invasive option
and that seemed to be the smallest cut and the better
surgery seemed to be the robot. (P1)
Intuition and common sense
For several patients, their preference for robotic surgery
seemed intuitive; it made sense to them that this pro-
cedure would be the better one. This was because they
understood it to be ‘more delicate and more precise’,
which should in turn facilitate a quicker recovery. Some
also valued the fact that it was a new, technologically
advanced procedure and felt that they would be taking
part in something pioneering:
This wonderful new robotic arm that’s gonna help me
heal faster by having this procedure so that I can get
on with a normal life … I’ll be able to recover faster
and be back at work and … won’t be a normal life but
a more normal life … the procedure would be more
compatible with my body and recovery and stuff. (P8)
Conversely, and illustrative of patients’ idiosyncratic
preferences, the only patient to express a preference for
open surgery expressed misgivings about being operated
on by a robot:
Uh I just didn’t think it was right … I’d rather have a
person doing it, and a person saying to me you know
this is what we’re doing. (P2)
Patient research and enquiry
Although for some patients their preferences seemed
more intuitive, many had also carried out their own
inquiries which included research using the Internet,
talking with previous patients and consulting with
friends and family with medical backgrounds. The re-
search that these patients carried out themselves
clearly influenced their preferences for robotic sur-
gery. This first patient described how a perceived lack
of direction in his initial consultation led him to carry
out his own research, which in turn seemed to pre-
empt the discussions and decision-making which took
place in his subsequent appointments. He had entered
these consultations with a clear idea of the treatment
which he wanted, and as a result could not recall hear-
ing much about the trial at all:
I have uh done my own little research and in response
to ‘well, uh what do you think?’ I said that I was
interested in the neo-bladder operation, in particular
the robotics … I read about (a patient who had this
particular operation) and then I looked into it a little
bit more and so the next time, I, I said, I expressed
interest in the robotic one, that was there. (P5)
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Other patients used Internet-based sources to supple-
ment the ‘official’ information that they were given in the
hospital. This information seemed to reinforce rather than
instigate their treatment preferences and decision-making.
Several patients, sometimes on the recommendations of
their surgeons had also watched online videos of the
robot, while others had met with former patients who had
received the surgery, an experience which they found
reassuring. While all patients were clear that their deci-
sions were their own, many described how they received
information and advice from family members and friends.
One half of patients described input from friends or family
members with medical backgrounds or connections,
which they used to help them make informed choices:
My sister lives in America and she, her in-laws work
in hospitals, micro-biologists, technicians sort of
thing. So I got them to um tell me what they thought,
they’d all worked in where the robot had been um
and came back with you know way to go you know, if
you get a choice don’t do anything else sort of thing.
(P9)
Individual circumstances and characteristics
Patients took into account their own medical histories
and ways of life when considering the different options
available to them as they made personalised treatment
choices. Some described illness histories, health events
and concerns over their current fitness in relation to
their preferences for the least invasive options:
When they said about surgery I thought ‘oh cuts’ and
that and healing. I knew that I had a dog bite years
ago and that took weeks to heal (and) I thought ‘God,
if I’m going to have a cut here and it’s going to heal,
it’s going to be agony for weeks sort of thing so as
soon as they said about that I said no, I wasn’t
interested’ (laughs). (P4)
Another patient described how her past experiences of
cancer intensified her determination to take up treat-
ment and return to normal family life as rapidly as pos-
sible. Similarly, participant one (below) described how
his 20-year battle with bladder cancer meant that he felt
a heightened need for control and decisive action as op-
posed to leaving anything to chance by entering the trial:
I think I’ve had 22 years of bladder cancer, most of its
been superficial and I’ve had, I imagine I’ve had at
least ten periods of different types of chemotherapy …
I’ve had BCG a number of times and it used to disable
me, it was so bad, like … and so I felt like I didn’t
want any more nonsense. I just wanted to get on with
it and get the bladder out. (P1)
Some patients also described how their particular life-
styles and life concerns favoured certain treatment options,
for example returning to work to meet particular deadlines
or keeping up with ‘energetic’ leisure pursuits following
keyhole surgery. This was most extreme for the patient in
his mid-40s who, at the point of interview, had decided
against surgery altogether (opting instead for BCG), due in
large part to the impact that the operation would have on
his sex life, which was of particular concern to him given
his young age and lifestyle:
My only concern is being a lot younger than the
gentleman that had it done (..) vanity as it is I still
quite enjoy a sex life. This gentleman was like in his
60s … well if I don’t have to have surgery why do it
even if there’s the slimmest of chances, it’s got to be
worth a go. (P8)
Clinical influences
Participants were influenced by their clinical team.
This influence occurred through direct and indirect
messages which patients interpreted from their clinical
encounters. Only a small number of patients felt that
their consultants conveyed equipoise or messages of
uncertainty with regards to the different surgery
options. These surgeons would not explicitly state
which would be the better method with a justification
of ‘not being sure yet’:
I think he was trying to be very much on the fence …
he said that I would be accepted for robotic surgery,
(.)… I didn’t really get (..) a feeling from him one way
or the other. (P9)
Others recalled the more general positive messages
about keyhole and robotics which they received from
their clinicians, which convinced them that this was the
route to go down:
Well, he was saying about you know smaller cuts and
that sort of thing and that uh, less to heal and quicker,
it’ll heal quicker and all that sort of thing yes,
everything in favour of it as I say … the fact that that
particular surgeon said ‘well at least it’s got a steadier
hand than me’; I thought well that’s something. (P4)
Many patients also interpreted more indirect or
subliminal messages during their clinical encounters. A
couple of patients recalled the positive discussions which
they had with their anaesthetists during their pre-
operative assessments, which in delivering good news
about their fitness to have keyhole surgery, helped to
reinforce impressions of this being the better method:
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When I went to my pre-op assessment with the an-
aesthetic team, which involved riding a bike mainly
and having my heart tested and things, they said to
me oh you seem fine, your hearts good, your blood
pressure blah de blah is all good um so you should
be fine for the procedure and my overall impres-
sion was (.) that if you were fit and well and good
enough (.) physically to do it, it was the best choice
… that everyone seemed to think that it was a
really good thing that I was fit and well because I
could have this procedure. (P6)
A number of patients were also aware of the strong
reputations of their surgeons in delivering pioneering ro-
botic surgery, and from this deduced that the robotic
option would also most likely be the surgeon’s preferred
method:
He’s quite well-renowned for robotic stuff so I im-
agine that he would have gone for robot … I don’t
know, I mean I would have thought he would be-
cause that is what they are doing. They are going
for robot surgery and hopefully it’s going to be
much better. (P1)
Patients not only described confidence in the surgeon
when it came to the robotic operation, they had also felt
that the method was well established and ‘tried and
tested’:
There seems to be a procedure that they’ve tried and
tested over the last 3 years. Well it says here 600
people have had the procedure just in (location name)
… So I don’t feel like it’s um a guinea pig situation. So
um, um so I’m taking it at face value really that that’s
the one they think I should have. (P6)
Similarly, whilst this next patient described how his
surgeon had countered his efforts to obtain ‘expert’ ad-
vice from him by suggesting a lack of definitive evidence,
the length of time in which the operation had been prac-
ticed was enough to reassure them:
I said to him ‘you’re the expert, you should be
advising me’. But he said ‘oh but we’re not sure yet’
um ‘what’s the best’ and I said ‘well how long have
you been doing for?’And I think he said ‘2 years’ but I
could be wrong. And so I said ‘I’ll go for the robot’
because you know it might be less invasive and easier
to get better’. (P1)
Both nurses felt that they presented equipoise as best
they could by emphasising that it is not known which
method is best. However, they also reflected on how
this could be difficult because many patients had
already formed clear ideas about which treatment they
wanted:
The main message …with the trial is, because we
don’t know which one is the better procedure in
outcomes after surgery, i.e. um recovery times,(.)
infection rates, pain control all those sorts of things.
But it’s you know the sorts of things we say to the
patients, because obviously they tend to latch onto
one arm of the trial and think that is the best one. It’s
quite difficult to sort of get them back on an even
keel to think well you know we don’t know whether
that is or not. (RN2)
It was felt that the consultants were effective at
explaining the different treatment options to patients,
but also considered that some consultants may pass
their own preferences for type of surgery onto their
patients:
Some of them do (..) um I think the consultant here
likes his robotic surgery but he also likes the trials as
well so that’s why he (.) you know he explains
everything so well to the patients I think so they are
fully informed when they do go away with the
information sheet. (RN2)
When asked for their views on why some patients ac-
cepted randomisation, one of the nurses considered that
having an existing relationship with the trial staff seemed
to be the key factor due to feelings of trust and familiarity:
I think mainly because some of the patients that we
randomise into the trial here were patients that I’d
treated before in another trial, so I think sometimes
that has a lot to do with it, that they know the people
that are in the room … I’d already looked after them
for 6/7 months beforehand, given them treatments,
been at the clinic appointments and I think they’re a
little bit (.) more trusting, I don’t know if trusting is
the right word, but I think because they feel
comfortable in the room with the people that are
there. (RN2)
The other research nurse considered that the only
noticeable difference between consenters and non-
consenters was the emotional wellbeing of the patient,
with more distressed patients less likely to enter the trial.
Although only based on two perspectives, these insights
again indicate the relevance of patients’ emotions, the
clinic environment and the relationships that patients
have with their clinicians for decision-making regarding
trials.
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Preferences for greater clinician input or involvement
Many patients would have liked greater direction from
their surgeon when making these decisions. Although
patients ultimately formed preferences for the type of
surgery they would receive, some patients also described
how their primary preference was for guidance and dir-
ection from their surgeon when making these choices.
In other words, it was not that they had a particular
preference for a type of surgery at the outset; rather that
they wanted the decision to be reached with input from
their clinician, and experienced a sense of unease and
frustration when this was not accomplished:
I said the only aspect of the trial I wasn’t happy with
was the randomisation because I felt that the decision
should be arrived at as a sort of a clinician decision
between the consultant and the patient. (P3)
I mean the fact of the matter is I don’t know anything
and so asking me that is just uh, just not on … I
would like to have a narrative account of what the
problem, of how it’s going be and what it’s, what the
alternatives are and I never did get it … So I went and
made up my mind on my own uh which now that I’m
over it I find that’s OK. I’m not regretting it (.) but um
it filled me with unease. (P5)
Both of these (older) patients also reflected on how
current models of patient-led consultation were ‘at odds’
with the values, expectations and preferences of their
generation for authoritative guidance from their
physicians:
Well, I, I come from an age where you do as your
doctor tells you whereas someone half my age (.)
might arrive at a consultation with a ream of print
outs from his PC explaining (what) he wanted done.
Um I don’t (.) think that’s the right way forward
anyway. (P3)
Discussion
This paper contributes to the small amount of evi-
dence from embedded qualitative studies which help
to explain recruitment difficulties experienced by
surgical trials. It identifies a perceived lack of equi-
poise between trial arms amongst our ‘non-con-
senter’ participants and draws attention to a number
of factors which explain patient preferences and
choices. As such, this study adds new insight to pre-
vious similar findings in this area and identifies im-
portant implications for future research aimed at
evaluating the effectiveness of surgical/technology in-
novations, particularly those already available as part
of routine practice.
In general, these study participants were well-informed
and had a good understanding and appreciation of the
trial and medical research more broadly. Most participants
seemed to correctly understand the purpose of the trial as
being to compare the different types of surgery, and felt
happy with their level of understanding. As in previous
surgical trials, participants understood the basic concept
of randomisation as having treatment allocation left to
chance, but could not accept this method of treatment
allocation because they could not accept the supposed
‘equipoise’ in this trial and that their clinician was genu-
inely uncertain [2, 10, 12].
As in previous studies, the main barrier to recruitment
into this surgical trial seems to have been the emergence
of clear treatment preferences amongst patients [2, 9–13].
In this embedded study, most of the patients who declined
randomisation did so because they had preferences for the
surgical method they would be given, which in most cases
was the robotic option. The ability of these patients to
choose their preferred treatment option in usual care
meant that they were unwilling to relinquish control by
accepting randomisation and with it the possibility that
they might not receive their preferred option, as similarly
demonstrated in a feasibility trial of childhood strabismus
surgery [23]. Patient preferences for type of surgery were
linked to their understandings of the different risks and
benefits attached to each method. Most patients saw the
benefits of keyhole/robotic surgery to be that it was less
invasive, requiring smaller cuts and producing less scar-
ring, smaller risk of infection and a shorter recovery
period than for open surgery.
Patients drew on multiple forms of knowledge and
expertise to inform their decision-making. Many had
sought additional information from ‘accredited’
sources of expertise, such as published research stud-
ies available on the Internet, and friends and family
members with medical backgrounds, whilst a few
looked to the narrative accounts and ‘experience-
based’ expertise of patients who had already under-
gone surgery [17]. Patients also drew on their own
personal, subjective and culturally framed knowledge
[18, 19]. For several patients their preference for ro-
botic surgery seemed intuitive. It made sense to them
(within their cultural frames of reference) that this
would be the better option; it was new and techno-
logically advanced whilst also perceived as sufficiently
‘tried and tested’. Patients also took into account their
own illness histories and lifestyles when weighing up
the different options available to them, to make what
could be considered personalised treatment choices.
These findings highlight the context dependent nature
of knowledge and decision-making [24, 25], and
illustrate well the argument that patients judge treat-
ment outcomes subjectively based on their personal
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circumstances [25]. This causes difficulties for the
practice of clinical equipoise in trials in so far as dif-
ferent people will attach different meanings to pre-
sented outcomes and may expect that these are taken
into consideration when planning treatment pathways.
Participants had also been influenced by their clinical
team, from whom they had expected and sought expert
guidance and direction. This influence occurred through
direct and indirect messages. Only a small number of
patients felt that their consultants conveyed equipoise or
messages of uncertainty with regards to the different
surgery options. As in previous surgical trials many
patients felt that their surgeon had openly favoured a
particular trial arm [2, 10–12], in this case the robotic
method. Many patients also interpreted indirect or sub-
liminal messages during their clinical encounters. These
‘indirect’ cues included positive comments made about
fitness and suitability for robotic surgery during pre-
operative assessments; the strong reputations of their
surgeons in delivering pioneering robotic surgery (and
assumed preferences for this technique), and the fact
that the ‘new method’ had become well- established at
these centres. In some ways this contrasts with the find-
ings of an embedded study in another surgical trial, in
which participants responded to loaded terminology in
favour of the established (as opposed to ‘experimental’)
treatment [2]. What both studies more importantly illus-
trate, however, is the salience of hidden messages in un-
wittingly shaping patient preferences, and the openness
of patients to such cues as they actively seek out ‘expert’
influence and confirmation.
Following this, a number of patients were explicit
about wanting greater input from their consultants when
making their treatment decisions [23]. This preference
aligns with research on decision-making preferences in
healthcare, which notes that whilst patients welcome the
opportunity to participate in decision-making it appears
they do not necessarily want to be responsible for deci-
sions, with a sizeable minority to a half preferring pas-
sive roles [26–28], compared with a much smaller (and
generally better educated, younger) minority who prefer
purely autonomous roles [27–29]. In this study, it was
the older (but well-educated) patients who expressed
greatest frustration at the lack of direction, even reflect-
ing on what could be conceptualised as a ‘culture clash’
between the values and expectations of their generation
and current medical models of patient-led choice and
calculated risk assessment [14–16]. These patients strug-
gled to accept randomisation not just because of the
preferences which they formed but because they had an
underlying expectation that their clinicians would make
treatment decisions based on individual clinical assess-
ments [9], thus further highlighting the need to context-
ualise knowledge, risk and decision-making [14, 16, 24].
Limitations and implications for further research
Recruitment to the qualitative study was slow and just
ten patient interviews were carried out. Although these
patients represented a homogenous group and sufficient
data were gained from these interviews to reach satur-
ation and enable meaningful analysis, it should also be
noted that a larger proportion of non-consenters to the
clinical trial declined to take part in the qualitative inter-
view. It is, therefore, possible that our sample included
participants who were more positive towards medical re-
search than the wider population of non-consenters who
were eligible for this embedded study. This in turn may
have biased our results in other ways given that a key
concern of the study was with patient perceptions of,
and engagement with research. However, it is unlikely
that this bias should detract significantly from our main
findings on patient preference and availability of choice
as barriers to trial recruitment.
Whilst our interviews with research nurses were
informative and provided some useful context it was
disappointing that only two out of six nurses agreed to
be interviewed, and only one of these interviews was
recorded, thus limiting any conclusions that can be
drawn from this data. Interviewing patients who decline
the trial is only one part of the picture, a more compre-
hensive investigation of recruitment issues could have
included observations of recruitment settings and prac-
tices, analysis and patient assessments of study docu-
ments and consultations and interviews with a larger
sample of clinician recruiters, as well as participants
who enter the trial. Ideally, this type of in-depth qualita-
tive investigation of trial processes should take place
before, or in the early stages of, the feasibility trial with
formal mechanisms for feeding back key findings and
designing and implementing practical changes to recruit-
ment materials (e.g. DVDs, communication checklists)
and staff training which could help to achieve a more ef-
fective presentation of equipoise. Such approaches have
been shown to improve recruitment into trials [10, 12],
and are recommended for further studies of this kind.
Given the apparent recruitment ‘success’ of a similar
trial being conducted in the US [3], exploration of inter-
continental differences in trial recruitment practices
could also be worthwhile.
Conclusion
Patients like to exercise informed choice over the type of
surgery they receive, and they like this choice to be
informed by their clinical team. In contrast with many
cancer ‘drug trials’, where trial entry might be the only
chance of receiving the ‘experimental’ treatment, for
surgical trials where the ‘new technology’ is routinely
available to patients there will likely be difficulties with
Harrop et al. Trials  (2016) 17:35 Page 9 of 11
recruitment. Going forward, an alternative option for
similar technology trials could be to use centres which
do not yet routinely use the technology under investiga-
tion, with access to the ‘new’ procedure restricted to trial
patients at these sites, thus incentivising patient entry
into the trial.
Greater attention could also be paid to how messages
about treatment options and the trial are conveyed, includ-
ing the more subliminal messages that pervade the whole
clinical setting; a strategy which was tried and found to be
effective in improving recruitment for another surgical trial
[10, 12]. However, if it is too difficult to challenge such
messages, for example if the ‘experimental’ treatment is
already entrenched in culture and practice (as seemed to be
the case in this trial), then questions should be asked about
whether equipoise can be presented and perceived with
conviction in such trials. Moreover, accommodating patient
wishes for clinician input and personalised consideration of
individual circumstances and characteristics, as is expected
by patients and practised in other areas of medical care,
presents a challenge in clinical trials and can leave patients
feeling frustrated and anxious if they perceive that this is
not being accomplished in their consultations. Clinical
equipoise is a difficult concept for patients to accept and
feelings of anxiety and frustration are probably more likely
to occur where there is not genuine conviction and belief in
clinical uncertainty amongst recruiting clinicians.
These issues challenge the feasibility of similar trials in
the future [11], and have implications for current agendas
on minimising ‘trial waste’; absent in which have been
questions concerning the appropriateness of using rando-
mised control trial (RCT) designs when evaluating certain
types of interventions [5–8]. These findings call for con-
sideration of whether alternative trial designs or methods
of generating evidence could be used when evaluating sur-
gical techniques which have already become established
and routinely available, and where there are likely to be
clear patient and physician preferences [1, 11, 13, 30].
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